{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:19:20Z","timestamp":1794809960194,"version":"4.9.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Melanoma in situ (MIS) and lentigo maligna (LM) present challenges, particularly in anatomically sensitive areas where surgical excision may result in morbidity. Topical imiquimod is increasingly used as a noninvasive alternative for MIS and LM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the efficacy, safety, and optimal treatment protocols of topical imiquimod for MIS and LM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A review of current literature was conducted using multiple databases. Studies reporting histologically confirmed MIS or LM treated with topical imiquimod were included. Outcomes included histological clearance, recurrence, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Thirteen studies encompassing 129 individual cases were analyzed (2000\u20132025). Reported histological clearance rates were approximately 84.5% (range, 77%\u201390%). Treatment duration ranged from 4 to 44 weeks, with most protocols lasting 8 to 16 weeks. Among cases with follow-up data, recurrence rates ranged from 0.5% to 15%. Common adverse effects included erythema and local irritation, and an inflammatory response was strongly associated with treatment success.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Topical imiquimod is a reasonable and efficacious treatment option for MIS and LM, particularly in anatomically challenging locations, and represents a valuable nonsurgical option with an acceptable safety profile; however, heterogeneous protocols, limited long-term follow-up, and small sample sizes limit certainty, and standardized treatment protocols are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000005174","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:00:21Z","timestamp":1779303621000},"page":"1027-1032","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Imiquimod for Melanoma in Situ and Lentigo Maligna: A Systematic Review"],"prefix":"10.1097","volume":"52","author":[{"given":"Jacob W.","family":"Fay","sequence":"first","affiliation":[{"name":"Northeast Ohio Medical University, Rootstown, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Kimball","sequence":"additional","affiliation":[{"name":"OhioHealth Riverside Methodist Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas W.","family":"Hartman","sequence":"additional","affiliation":[{"name":"Northeast Ohio Medical University, Rootstown, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Kuceki","sequence":"additional","affiliation":[{"name":"OhioHealth Riverside Methodist Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"R1-20261116","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.0022-202X.2005.23852.x","article-title":"Increasing incidence of lentigo maligna melanoma subtypes: Northern California and national trends 1990-2000","volume":"125","author":"Swetter","year":"2005","journal-title":"J Invest Dermatol"},{"key":"R2-20261116","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0190-9622(95)90282-1","article-title":"Lentigo maligna and lentigo maligna melanoma","volume":"33","author":"Cohen","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"R3-20261116","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaad.2007.09.023","article-title":"Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases","volume":"58","author":"Hazan","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R4-20261116","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-4632.2010.04423.x","article-title":"Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery","volume":"49","author":"Erickson","year":"2010","journal-title":"Int J Dermatol"},{"key":"R5-20261116","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/archderm.1994.01690080074010","article-title":"Lentigo maligna of the head and neck. Results of treatment by radiotherapy","volume":"130","author":"Tsang","year":"1994","journal-title":"Arch Dermatol"},{"key":"R6-20261116","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2015.05.022","article-title":"A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance","volume":"73","author":"Mora","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R7-20261116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/0001555579207132","article-title":"Cutaneous side effects from laser treatment of the skin: skin cancer, scars, wounds, pigmentary changes, and purpura\u2014use of pulsed dye laser, copper vapor laser, and argon laser","volume":"207","author":"Haedersdal","year":"1999","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"R9-20261116","first-page":"16","article-title":"Changes in skin cancer management","volume":"3","author":"Naylor","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"key":"R10-20261116","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.clindermatol.2013.08.020","article-title":"Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies","volume":"31","author":"Bahner","year":"2013","journal-title":"Clin Dermatol"},{"key":"R11-20261116","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1524-4725.2011.02194.x","article-title":"Basic pharmacology of topical imiquimod, 5-fluorouracil, and diclofenac for the dermatologic surgeon","volume":"38","author":"Desai","year":"2012","journal-title":"Dermatol Surg"},{"issue":"Suppl 2","key":"R12-20261116","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157","author":"Sch\u00f6n","year":"2007","journal-title":"Br J Dermatol"},{"key":"R14-20261116","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1046\/j.1365-2133.2000.03787.x","article-title":"Imiquimod: a novel treatment for lentigo maligna","volume":"143","author":"Ahmed","year":"2000","journal-title":"Br J Dermatol"},{"key":"R15-20261116","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000073101","article-title":"Topical treatment of lentigo maligna melanoma with imiquimod 5% cream","volume":"207","author":"Borucki","year":"2003","journal-title":"Dermatology"},{"key":"R16-20261116","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/archderm.139.7.943","article-title":"Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream","volume":"139","author":"Chapman","year":"2003","journal-title":"Arch Dermatol"},{"key":"R17-20261116","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/archderm.139.7.944","article-title":"Extensive lentigo maligna clearing with topical imiquimod","volume":"139","author":"Epstein","year":"2003","journal-title":"Arch Dermatol"},{"key":"R18-20261116","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archdermatol.2012.270","article-title":"A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions","volume":"148","author":"Hyde","year":"2012","journal-title":"Arch Dermatol"},{"key":"R19-20261116","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2133.2006.07476.x","article-title":"Imiquimod in the treatment of lentigo maligna","volume":"155","author":"Rajpar","year":"2006","journal-title":"Br J Dermatol"},{"key":"R20-20261116","first-page":"34","article-title":"Topical imiquimod for management of recurrent lentigo maligna melanoma in situ","volume":"28","author":"Bartenjev","year":"2020","journal-title":"Acta Dermatovenerol Croat"},{"key":"R21-20261116","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/IOP.0000000000000554","article-title":"Periocular melanoma in situ treated with imiquimod","volume":"32","author":"Elia","year":"2016","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R22-20261116","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1524-4725.2012.02362.x","article-title":"Melanoma in situ treated successfully using imiquimod after nonclearance with surgery: review of the literature","volume":"38","author":"Ellis","year":"2012","journal-title":"Dermatol Surg"},{"key":"R23-20261116","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2133.2004.05983.x","article-title":"A pilot study of treatment of lentigo maligna with 5% imiquimod cream","volume":"151","author":"Fleming","year":"2004","journal-title":"Br J Dermatol"},{"key":"R24-20261116","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jid.2019.07.725","article-title":"A distinct pretreatment immune gene signature in lentigo maligna is associated with imiquimod response","volume":"140","author":"Halse","year":"2020","journal-title":"J Invest Dermatol"},{"key":"R25-20261116","first-page":"1136","article-title":"Ocular effects of imiquimod with treatment of eyelid melanoma in situ","volume":"33","author":"Murchison","year":"2007","journal-title":"Dermatol Surg"},{"key":"R26-20261116","first-page":"1543","article-title":"Successful treatment of persistent melanoma in situ with 5% imiquimod cream","volume":"30","author":"Mu\u00f1oz","year":"2004","journal-title":"Dermatol Surg"},{"key":"R27-20261116","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2230.2004.01452.x","article-title":"Topical imiquimod immunotherapy in the management of lentigo maligna","volume":"29","author":"Powell","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"R28-20261116","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1365-2133.2009.09032.x","article-title":"Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up","volume":"160","author":"Powell","year":"2009","journal-title":"Br J Dermatol"},{"key":"R29-20261116","first-page":"149","article-title":"Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports","volume":"79","author":"Spenny","year":"2007","journal-title":"Cutis"},{"key":"R30-20261116","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/archderm.141.4.510","article-title":"Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod","volume":"141","author":"Wolf","year":"2005","journal-title":"Arch Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:00:49Z","timestamp":1794808849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000005174","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}